

Klaus Elenius

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/334929/publications.pdf>

Version: 2024-02-01

95
papers

6,051
citations

66234

42
h-index

71532

76
g-index

97
all docs

97
docs citations

97
times ranked

7364
citing authors

#	ARTICLE	IF	CITATIONS
1	An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. <i>Cancer Research Communications</i> , 2022, 2, 10-27.	0.7	2
2	Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 564-576.	1.9	4
3	Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations. <i>Cancers</i> , 2021, 13, 1120.	1.7	10
4	Therapeutic Potential of Targeting the SUMO Pathway in Cancer. <i>Cancers</i> , 2021, 13, 4402.	1.7	25
5	Combined genetic and chemical screens indicate protective potential for EGFR inhibition to cardiomyocytes under hypoxia. <i>Scientific Reports</i> , 2021, 11, 16661.	1.6	3
6	Genetic and functional implications of an exonic TRIM55 variant in heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 138, 222-233.	0.9	11
7	ErbB4 regulates the oocyte microenvironment during folliculogenesis. <i>Human Molecular Genetics</i> , 2020, 29, 2813-2830.	1.4	16
8	The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration. <i>Journal of Biological Chemistry</i> , 2020, 295, 11559-11571.	1.6	11
9	Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	4
10	Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation. <i>PLoS ONE</i> , 2019, 14, e0222814.	1.1	23
11	Decorin Expression in Human Vulva Carcinoma: Oncosuppressive Effect of Decorin cDNA Transduction on Carcinoma Cells. <i>Journal of Histochemistry and Cytochemistry</i> , 2019, 67, 511-522.	1.3	3
12	An unbiased in vitro screen for activating epidermal growth factor receptor mutations. <i>Journal of Biological Chemistry</i> , 2019, 294, 9377-9389.	1.6	17
13	Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling. <i>Circulation</i> , 2019, 139, 2570-2584.	1.6	113
14	Gamma-secretase-dependent signaling of receptor tyrosine kinases. <i>Oncogene</i> , 2019, 38, 151-163.	2.6	46
15	The Mutational Profile of Unicystic Ameloblastoma. <i>Journal of Dental Research</i> , 2019, 98, 54-60.	2.5	55
16	ErbB4 tyrosine kinase inhibition impairs neuromuscular development in zebrafish embryos. <i>Molecular Biology of the Cell</i> , 2019, 30, 209-218.	0.9	7
17	Abstract 1780: iSCREAM - an unbiased pipeline to screen for activating kinase mutations. , 2019, , .		0
18	Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin. <i>Scientific Reports</i> , 2018, 8, 16579.	1.6	9

#	ARTICLE	IF	CITATIONS
19	Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target. BMC Cardiovascular Disorders, 2018, 18, 196.	0.7	11
20	Abstract 3500: A pipeline to identify driver mutations. , 2018, , .		0
21	SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase. Journal of Biological Chemistry, 2017, 292, 19890-19904.	1.6	20
22	Genome-wide screen of gamma-secretase-mediated intramembrane cleavage of receptor tyrosine kinases. Molecular Biology of the Cell, 2017, 28, 3123-3131.	0.9	46
23	Human Metaplastic Breast Carcinoma and Decorin. Cancer Microenvironment, 2017, 10, 39-48.	3.1	10
24	Activating ERBB4 mutations in non-small cell lung cancer. Oncogene, 2016, 35, 1283-1291.	2.6	57
25	Novel Targets for the Treatment of Ameloblastoma. Journal of Dental Research, 2015, 94, 237-240.	2.5	57
26	Abstract 139: Activating ERBB4 mutations in non-small cell lung cancer. , 2015, , .		0
27	ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer. PLoS ONE, 2014, 9, e102388.	1.1	5
28	Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis. Breast Cancer Research, 2014, 16, 501.	2.2	27
29	ErbB4, a Receptor Tyrosine Kinase, Coordinates Organization of the Seminiferous Tubules in the Developing Testis. Molecular Endocrinology, 2014, 28, 1534-1546.	3.7	8
30	Hypoxia-inducible Factor-1 α Induces ErbB4 Signaling in the Differentiating Mammary Gland. Journal of Biological Chemistry, 2014, 289, 22459-22469.	1.6	7
31	High frequency of BRAF V600E mutations in ameloblastoma. Journal of Pathology, 2014, 232, 492-498.	2.1	240
32	CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecologic Oncology, 2013, 129, 179-187.	0.6	25
33	ERBB4 Mutations that Disrupt the Neuregulin-ErbB4 Pathway Cause Amyotrophic Lateral Sclerosis Type 19. American Journal of Human Genetics, 2013, 93, 900-905.	2.6	123
34	Abstract 4407: Structural and biochemical analysis of ERBB4 mutations in cancer.. , 2013, , .		0
35	Abstract A31: Regulation of ErbB4 receptor tyrosine kinase by the SUMO system. , 2013, , .		0
36	ErbB4 Modulates Tubular Cell Polarity and Lumen Diameter during Kidney Development. Journal of the American Society of Nephrology: JASN, 2012, 23, 112-122.	3.0	54

#	ARTICLE	IF	CITATIONS
37	Protein Inhibitor of Activated STAT3 (PIAS3) Protein Promotes SUMOylation and Nuclear Sequestration of the Intracellular Domain of ErbB4 Protein. <i>Journal of Biological Chemistry</i> , 2012, 287, 23216-23226.	1.6	35
38	Translation of a Research-Based Genetic Test on a Rare Syndrome into Clinical Service Testing, with Sotos Syndrome As an Example. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 1188-1194.	0.3	3
39	Interaction with ErbB4 Promotes Hypoxia-inducible Factor-1 α Signaling. <i>Journal of Biological Chemistry</i> , 2012, 287, 9659-9671.	1.6	40
40	Proteolytic Processing of ErbB4 in Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e39413.	1.1	37
41	Systemic Analysis of Gene Expression Profiles Identifies ErbB3 as a Potential Drug Target in Pediatric Alveolar Rhabdomyosarcoma. <i>PLoS ONE</i> , 2012, 7, e50819.	1.1	9
42	Function of <i>ERBB4</i> is determined by alternative splicing. <i>Cell Cycle</i> , 2011, 10, 2647-2657.	1.3	95
43	Interaction between Marrow-Derived Human Mesenchymal Stem Cells and Peripheral Blood Mononuclear Cells in Endothelial Cell Differentiation. <i>Scandinavian Journal of Surgery</i> , 2011, 100, 216-222.	1.3	14
44	ErbB Targeted Drugs and Angiogenesis. <i>Current Vascular Pharmacology</i> , 2010, 8, 421-431.	0.8	11
45	Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth. <i>Experimental Cell Research</i> , 2010, 316, 1169-1178.	1.2	12
46	Cell Death or Survival Promoted by Alternative Isoforms of ErbB4. <i>Molecular Biology of the Cell</i> , 2010, 21, 4275-4286.	0.9	54
47	EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 185-201.	1.0	32
48	Potential of ErbB4 antibodies for cancer therapy. <i>Future Oncology</i> , 2010, 6, 37-53.	1.1	31
49	Somatic Mutations of ErbB4. <i>Journal of Biological Chemistry</i> , 2009, 284, 5582-5591.	1.6	55
50	ErbB4 Splice Variants Cyt1 and Cyt2 Differ by 16 Amino Acids and Exert Opposing Effects on the Mammary Epithelium In Vivo. <i>Molecular and Cellular Biology</i> , 2009, 29, 4935-4948.	1.1	68
51	Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor. <i>BMC Cell Biology</i> , 2009, 10, 5.	3.0	4
52	Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. <i>Oncogene</i> , 2009, 28, 1309-1319.	2.6	54
53	The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. <i>Microvascular Research</i> , 2009, 78, 278-285.	1.1	37
54	Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. <i>Radiotherapy and Oncology</i> , 2009, 92, 388-392.	0.3	46

#	ARTICLE	IF	CITATIONS
55	Mutated <i>ERBB4</i> : a novel drug target in metastatic melanoma?. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 708-710.	1.5	12
56	Pim-1 Kinase Expression Predicts Radiation Response in Squamocellular Carcinoma of Head and Neck and Is under the Control of Epidermal Growth Factor Receptor. <i>Neoplasia</i> , 2009, 11, 629-IN1.	2.3	65
57	Role of ErbB4 in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 259-268.	1.0	121
58	Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4162-4167.	3.3	90
59	ErbB4 and its Isoforms: Patentable Drug Targets?. <i>Recent Patents on DNA & Gene Sequences</i> , 2008, 2, 27-33.	0.7	9
60	Association of <i>Wwox</i> with ErbB4 in Breast Cancer. <i>Cancer Research</i> , 2007, 67, 9330-9336.	0.4	99
61	O-Sulfated Bacterial Polysaccharides with Low Anticoagulant Activity Inhibit Metastasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 547-556.	1.5	30
62	Concomitant chemoradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. <i>Radiotherapy and Oncology</i> , 2007, 85, 138-145.	0.3	7
63	Proteome Analysis of Cultivated Vascular Smooth Muscle Cells from a CADASIL Patient. <i>Molecular Medicine</i> , 2007, 13, 305-314.	1.9	36
64	Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. <i>Oncogene</i> , 2007, 26, 6905-6914.	2.6	63
65	Intra- and extracellular signaling by endothelial neuregulin-1. <i>Experimental Cell Research</i> , 2007, 313, 2896-2909.	1.2	42
66	Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 441-450.	1.8	37
67	Proteolytic Cleavage and Phosphorylation of a Tumor-associated ErbB4 Isoform Promote Ligand-independent Survival and Cancer Cell Growth. <i>Molecular Biology of the Cell</i> , 2006, 17, 67-79.	0.9	129
68	The Intracellular Domain of ErbB4 Induces Differentiation of Mammary Epithelial Cells. <i>Molecular Biology of the Cell</i> , 2006, 17, 4118-4129.	0.9	81
69	Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells. <i>Clinical Cancer Research</i> , 2006, 12, 4103-4111.	3.2	231
70	Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II β gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. <i>Annals of Oncology</i> , 2005, 16, 273-278.	0.6	585
71	Cleavable ErbB4 Isoform in Estrogen Receptor-Regulated Growth of Breast Cancer Cells. <i>Cancer Research</i> , 2005, 65, 1384-1393.	0.4	169
72	DNA Topoisomerase I Is a Cofactor for c-Jun in the Regulation of Epidermal Growth Factor Receptor Expression and Cancer Cell Proliferation. <i>Molecular and Cellular Biology</i> , 2005, 25, 5040-5051.	1.1	47

#	ARTICLE	IF	CITATIONS
73	Inhibition by the Soluble Syndecan-1 Ectodomains Delays Wound Repair in Mice Overexpressing Syndecan-1. <i>Journal of Biological Chemistry</i> , 2004, 279, 41928-41935.	1.6	93
74	ErbB4 is downregulated in renal cell carcinoma A quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. <i>Acta Oncologica</i> , 2004, 43, 453-459.	0.8	23
75	Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1585-92.	1.9	166
76	Endothelial cellâ€“Matrix interactions. <i>Microscopy Research and Technique</i> , 2003, 60, 13-22.	1.2	92
77	Angiopoietinâ€“regulated recruitment of vascular smooth muscle cells by endothelialâ€“derived heparin binding EGFâ€“like growth factor. <i>FASEB Journal</i> , 2003, 17, 1609-1621.	0.2	106
78	Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 5346-57.	3.2	88
79	ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. <i>Clinical Cancer Research</i> , 2002, 8, 3054-64.	3.2	141
80	N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration. <i>EMBO Journal</i> , 2001, 20, 3342-3350.	3.5	115
81	ErbB4 and Its Isoforms Selective Regulation of Growth Factor Responses by Naturally Occurring Receptor Variants. <i>Trends in Cardiovascular Medicine</i> , 2000, 10, 304-310.	2.3	115
82	A Natural ErbB4 Isoform That Does Not Activate Phosphoinositide 3-Kinase Mediates Proliferation but Not Survival or Chemotaxis. <i>Journal of Biological Chemistry</i> , 2000, 275, 8641-8649.	1.6	148
83	Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. <i>Oncogene</i> , 1999, 18, 2607-2615.	2.6	150
84	Heparin-binding EGF-like growth factor in the human prostate: Synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. , 1998, 68, 328-338.		38
85	A Novel Juxtamembrane Domain Isoform of HER4/ErbB4. <i>Journal of Biological Chemistry</i> , 1997, 272, 26761-26768.	1.6	191
86	Expression of Small Extracellular Chondroitin/Dermatan Sulfate Proteoglycans Is Differentially Regulated in Human Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 12730-12737.	1.6	44
87	Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. <i>EMBO Journal</i> , 1997, 16, 1268-1278.	3.5	325
88	Suppression of Syndecan-1 Expression in Endothelial Cells by Tumor Necrosis Factor- α . <i>Journal of Biological Chemistry</i> , 1996, 271, 18759-18766.	1.6	55
89	The Epidermal Growth Factor Receptor Couples Transforming Growth Factor- β , Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4. <i>Journal of Biological Chemistry</i> , 1996, 271, 20047-20052.	1.6	146
90	Function of the syndecans - a family of cell surface proteoglycans. <i>Journal of Cell Science</i> , 1994, 107, 2975-2982.	1.2	129

#	ARTICLE	IF	CITATIONS
91	Syndecan: Regulator of Cell Morphology and Growth Factor Action at the Cell-matrix Interface.. Trends in Glycoscience and Glycotechnology, 1993, 5, 107-120.	0.0	21
92	Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Experimental Cell Research, 1992, 200, 444-451.	1.2	90
93	Syndecan, a regulator of cell behaviour, is lost in malignant transformation. Biochemical Society Transactions, 1991, 19, 1069-1072.	1.6	10
94	Induced expression of syndecan in healing wounds.. Journal of Cell Biology, 1991, 114, 585-595.	2.3	226
95	Syndecan from embryonic tooth mesenchyme binds tenascin. Cell Differentiation and Development, 1989, 27, 80.	0.4	0